Academics will also work to validate company’s recurrence test ColoPrint.

Researchers from The University of Texas MD Anderson Cancer Center, The Netherlands Cancer Institute (NKI), and Agendia are joining forces in a collaboration aimed at  improving diagnosis and treatment options of colorectal cancer patients.They will integrate various genomic and proteomic technologies to study patterns of gene and protein expression in cancerous tumors. The university group will also perform validation studies of the company’s developmental-stage prognostic tool.

As part of the arrangement, the scientists will analyze colorectal cancer samples, studying their active genome, mutation status, and protein activation. Results will be combined with pathological and clinical data to provide insight into the biology of individual patients’ tumors and why patients often have different prognosis and varied responses to the same treatment.

Scientists from MD Anderson and NKI will also try to validate Agendia’s colon cancer recurrence test ColoPrint®. The test is designed to stratify stage II colon cancer patients into either low risk or high risk of experiencing a disease recurrence.

Previous articleRoche to Supply UCLA Centers with Technologies and Support for Biomarker Discovery
Next articleSupreme Court Decision in Stanford v. Roche Does Not Change Bayh-Dole